Furthermore, the 52 patients with KRAS hotspot-mutant NSCLC had a median OS of 24.3 months (95% CI, 15.9-32.7 months) from initial metastasis diagnosis and 7.2 months (95% CI, 3.3-11.2 months) from initial phase I clinic visit, whereas those without KRAS mutations had a median OS of 27.2 months (95% CI, 22.3-32.1 months; p=0.9) and 9.2 months (95% CI, 5.9-12.5 months; p=0.48). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.